References
[1] EASL Recommendations on Treatment of Hepatitis C 2016.LID - S0168-8278(16)30489-5 [pii]LID - 10.1016/j.jhep.2016.09.001 [doi]. J Hepatol. 2016 .
[2] Cha A, Budovich A. Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. P T. 2014. 39(5): 345-52.
[3] Soriano V, Barreiro P, de Mendoza C, Pena JM. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. Antivir Ther. 2016. 21(1): 91-2.
[4] Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015. 9: 164.
[5] Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2016. 64(1): 234-8.
[6] Debes JD, Ricci P. Acute liver failure during hepatitis C treatment with sofosbuvir and ledipasvir. Dig Liver Dis. 2015. 47(12): 1091-2.
[7] Gupta N, Bodin R, Sule S. Autoimmune Hepatitis in Association With Sofosbuvir. Am J Ther. 2015 .
[8] Padegimas A, Forde KA, Goldberg LR, Birati EY. Myo-pericarditis secondary to ledipasvir-sofosbuvir therapy. J Hepatol. 2016. 64(5): 1196-8.
[9] Brainard DM, McHutchison JG. Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med. 2015. 373(19): 1888.
[10] Fontaine H, Lazarus A, Pol S, et al. Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med. 2015. 373(19): 1886-8.
[11] Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol. 2016. 64(4): 790-9.
[12] Wanchoo R, Thakkar J, Schwartz D, Jhaveri KD. Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury. Am J Gastroenterol. 2016. 111(1): 148-9.
[13] Renard S, Borentain P, Salaun E, et al. Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir. Chest. 2016. 149(3): e69-73.
[14] Sarkar S, Mitchell KA, Lim JK, Oikonomou I, Jakab S. Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. ACG Case Rep J. 2015. 3(1): 42-4.
[15] Izzo I, AUID- Oho, Zanotti P, et al. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C. Infection. 2016 .
[16] Syal G, Heldenbrand SD, Duarte-Rojo A. Seizures as a Potential Complication of Treatment With Simeprevir and Sofosbuvir. Am J Ther. 2016. 23(2): e570-1.
[17] Cheung EJ, Jedrych JJ, English JC 3rd. Sofosbuvir-Induced Erythrodermic Pityriasis Rubra Pilaris-Like Drug Eruption. J Drugs Dermatol. 2015. 14(10): 1161-2.
[18] Scott GD, Rieger KE. New-onset cutaneous lichen planus following therapy for hepatitis C with ledipasvir-sofosbuvir. J Cutan Pathol. 2016. 43(4): 408-9.
[19] Chin-Loy K, Galaydh F, Shaikh S. Retinopathy and Uveitis Associated with Sofosbuvir Therapy for Chronic Hepatitis C Infection. Cureus. 2016. 8(5): e597.
[20] McQuaid T, Savini C, Seyedkazemi S. Sofosbuvir, a Significant Paradigm Change in HCV Treatment. J Clin Transl Hepatol. 2015. 3(1): 27-35.
[21] In brief: severe bradycardia with sofosbuvir and amiodarone. Med Lett Drugs Ther. 2015. 57(1466): 58.
[22] FDA. FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug. 2015-3-24. http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm.
閱讀更多 蔡晧東醫生 的文章
